KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD

American Journal of Kidney Diseases

Volumn 63, Issue 5, 2014, Pages 713-735

  Inker, Lesley A ^a   Astor, Brad C ^b   Fox, Chester H ^c   Isakova, Tamara ^d   Lash, James P ^e   Peralta, Carmen A ^f   Kurella Tamura, Manjula ^g   Feldman, Harold I ^h  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

albuminuria; chronic kidney diseases (CKD) staging; clinical practice guideline; Estimated glomerular filtration rate (eGFR); Index Words; kidney disease progression; Kidney Disease Quality Outcomes Quality Initiative (KDOQI); Kidney Disease: Improving Global Outcomes (KDIGO)

Indexed keywords

BIOLOGICAL MARKER;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; DISEASE CLASSIFICATION; GLOMERULUS FILTRATION RATE; KIDNEY INJURY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

ALBUMINURIA; CHRONIC KIDNEY DISEASES (CKD) STAGING; CLINICAL PRACTICE GUIDELINE; ESTIMATED GLOMERULAR FILTRATION RATE (EGFR); KIDNEY DISEASE PROGRESSION; KIDNEY DISEASE QUALITY OUTCOMES QUALITY INITIATIVE (KDOQI); KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO);

DISEASE MANAGEMENT; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84898869053     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.01.416     Document Type: Article

References (83)

1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 suppl 2 2002 S1 S266
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 2013 1 150
3. A.S. Levey A decade after the KDOQI CKD guidelines Am J Kidney Dis 60 2012 683 685
4. B.L. Kasiske, and K.U. Eckardt Evidence and outcomes in CKD Am J Kidney Dis 59 2012 492 494
5. Kidney Disease: Improving Global Outcomes (KDIGO). About us. http://kdigo.org/home/about-us/. Accessed November 26, 2013.
6. A.S. Levey, P.E. de Jong, and J. Coresh et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report Kidney Int 80 2011 17 28
7. K. Matsushita, M. van der Velde, and B.C. Astor et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
8. M. Van der Velde, K. Matsushita, and J. Coresh et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts Kidney Int 79 2011 1341 1352
9. B.C. Astor, K. Matsushita, and R.T. Gansevoort et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts Kidney Int 79 2011 1331 1340
10. R.T. Gansevoort, K. Matsushita, and M. van der Velde et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts Kidney Int 80 2011 93 104
11. V.A. Moyer U.S. Preventive Services Task Force Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 567 570
12. A.V. Chobanian, G.L. Bakris, and H.R. Black et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
13. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 suppl 1 2013 S11 S66
14. National Kidney Disease Education Program (NKDEP). Creatinine Standardization. http://nkdep.nih.gov/lab-evaluation/gfr/creatinine-standardization.shtml. Accessed November 6, 2013.
15. A.S. Levey, L.A. Stevens, and C.H. Schmid et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
16. T.B. Andersen, L. Jødal, and M. Boegsted et al. GFR prediction from cystatin C and creatinine in children: effect of including body cell mass Am J Kidney Dis 59 2012 50 57
17. L.A. Inker, C.H. Schmid, and H. Tighiouart et al. Estimating glomerular filtration rate from serum creatinine and cystatin C N Engl J Med 367 2012 20 29
18. E.S. Schaeffner, N. Ebert, and P. Delanaye et al. Two novel equations to estimate kidney function in persons aged 70 years or older Ann Intern Med 157 2012 471 481
19. B.W. Teo, H. Xu, and Y.Y. Koh et al. Estimating kidney function in a multiethnic Asian population with multiple filtration markers Am J Kidney Dis 60 2012 500 502
20. M.G. Shlipak, K. Matsushita, and J. Ärnlöv et al. Cystatin C versus creatinine in determining risk based on kidney function N Engl J Med 369 2013 932 943
21. J.C. Lieske, O. Bondar, and W.G. Miller et al. A reference system for urinary albumin: current status Clin Chem Lab Med 51 2013 981 989
22. B.R. Hemmelgarn, F. Clement, and B.J. Manns et al. Overview of the Alberta Kidney Disease Network BMC Nephrol 10 2009 30
23. T.C. Turin, J. Coresh, and M. Tonelli et al. One-year change in kidney function is associated with an increased mortality risk Am J Nephrol 36 2012 41 49
24. T.C. Turin, J. Coresh, and M. Tonelli et al. Short-term change in kidney function and risk of end-stage renal disease Nephrol Dial Transplant 27 2012 3835 3843
25. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 76 2009 337 414
26. National Kidney Foundation KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 suppl 1 2004 S1 S290
27. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published online ahead of print December 18, 2013]. JAMA.
28. Systolic Blood Pressure Intervention Trial (SPRINT). Justification for CKD subgroup. https://www.sprinttrial.org/public/dspSprintScience.cfm. Accessed November 27, 2013.
29. L.F. Fried, N. Emanuele, and J.H. Zhang et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 2013 1892 1903
30. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 60 2012 850 886
31. A. Patel, S. MacMahon, and J. Chalmers et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
32. W. Duckworth, C. Abraira, and T. Moritz et al. Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
33. H.C. Gerstein, M.E. Miller, and R.P. Byington et al. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
34. B.C. Kwan, M.A. Murtaugh, and S. Beddhu Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease Clin J Am Soc Nephrol 2 2007 992 998
35. C.P. Kovesdy, J.E. Anderson, and K. Kalantar-Zadeh Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis Am J Kidney Dis 49 2007 581 591
36. A.C. Ricardo, M. Madero, and W. Yang et al. Adherence to a healthy lifestyle and all-cause mortality in CKD Clin J Am Soc Nephrol 8 2013 602 609
37. F. Dumler, and C. Kilates Prospective nutritional surveillance using bioelectrical impedance in chronic kidney disease patients J Ren Nutr 15 2005 148 151
38. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO clinical practice guideline for anemia in chronic kidney disease Kidney Int Suppl 2 2012 279 335
39. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 76 2009 S1 S130
40. Institute of Medicine (IOM). Sodium intake in populations: assessment of evidence, 2013 report. http://iom.edu/Reports/2013/Sodium-Intake-in-Populations-Assessment-of-Evidence/Report-Brief051413.aspx. Accessed January 7, 2014.
41. D.E. Weiner, H. Tighiouart, and E.F. Elsayed et al. The Framingham predictive instrument in chronic kidney disease J Am Coll Cardiol 50 2007 217 224
42. V. Menon, T. Greene, and X. Wang et al. C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease Kidney Int 68 2005 766 772
43. C. Faul, A.P. Amaral, and B. Oskouei et al. FGF23 induces left ventricular hypertrophy J Clin Invest 121 2011 4393 4408
44. M.J. Jardine, T. Ninomiya, and V. Perkovic et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial J Am Coll Cardiol 56 2010 956 965
45. P.J. Best, S.R. Steinhubl, and P.B. Berger et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 155 2008 687 693
46. S. Balamuthusamy, L. Srinivasan, and M. Verma et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Am Heart J 155 2008 791 805
47. I.S. Anand, K. Bishu, T.S. Rector, A. Ishani, M.A. Kuskowski, and J.N. Cohn Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure Circulation 120 2009 1577 1584
48. H.L. Hillege, D. Nitsch, and M.A. Pfeffer et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure Circulation 113 2006 671 678
49. E. Erdmann, P. Lechat, P. Verkenne, and H. Wiemann Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure Eur J Heart Fail 3 2001 469 479
50. J.F. Mann, R.E. Schmieder, and M. McQueen et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
51. R. Lakhdar, M.H. Al-Mallah, and D.E. Lanfear Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials J Card Fail 14 2008 181 188
52. D.N. Juurlink, M.M. Mamdani, and D.S. Lee et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
53. R.K. Mishra, Y. Li, and A.C. Ricardo et al. Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]) Am J Cardiol 111 2013 432 438
54. R. Tagore, L.H. Ling, H. Yang, H.Y. Daw, Y.H. Chan, and S.K. Sethi Natriuretic peptides in chronic kidney disease Clin J Am Soc Nephrol 3 2008 1644 1651
55. Y. Takami, T. Horio, and Y. Iwashima et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF Am J Kidney Dis 44 2004 420 428
56. N.A. Abbas, R.I. John, and M.C. Webb et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease Clin Chem 51 2005 2059 2066
57. G.N. Wood, B. Keevil, and J. Gupta et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study Nephrol Dial Transplant 18 2003 1610 1615
58. E.J. Lamb, C. Kenny, and N.A. Abbas et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay Am J Kidney Dis 49 2007 507 516
59. K.J. Lipska, C.J. Bailey, and S.E. Inzucchi Use of metformin in the setting of mild-to-moderate renal insufficiency Diabetes Care 34 2011 1431 1437
60. S.R. Salpeter, E. Greyber, G.A. Pasternak, and E.E. Salpeter Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 4 2010 CD002967
61. US Food and Drug Administration. FDA Drug Safety Communication (2010): new warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed January 7, 2014.
62. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) Am J Transplant 13 2013 232 235
63. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury Kidney Int 2 2012 1 138
64. A.M. O'Hare, A.I. Choi, and D. Bertenthal et al. Age affects outcomes in chronic kidney disease J Am Soc Nephrol 18 2007 2758 2765
65. L.S. Dalrymple, R. Katz, and B. Kestenbaum et al. Chronic kidney disease and the risk of end-stage renal disease versus death J Gen Intern Med 26 2011 379 385
66. A.H. Moss Revised dialysis clinical practice guideline promotes more informed decision-making Clin J Am Soc Nephrol 5 2010 2380 2383
67. A.W. Williams, A.C. Dwyer, and A.A. Eddy et al. Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology Clin J Am Soc Nephrol 7 2012 1664 1672
68. M.K. Tamura, and D.E. Meier Five policies to promote palliative care for patients with ESRD Clin J Am Soc Nephrol 8 2013 1783 1790
69. J.L. Carter, C.R. Tomson, and P.E. Stevens et al. Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review Nephrol Dial Transplant 21 2006 3031 3037
70. K.L. Heathcote, M.P. Wilson, and D.W. Quest et al. Prevalence and duration of exercise induced albuminuria in healthy people Clin Invest Med 32 2009 E261 E265
71. V.M. Vehaskari Orthostatic proteinuria Arch Dis Child 57 1982 729 730
72. A.K. Leung, and A.H. Wong Proteinuria in children Am Fam Physician 82 2010 645 651
73. J.E. Howey, M.C. Browning, and C.G. Fraser Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation Clin Chem 33 1987 2034 2038
74. C.A. Boger, M.H. Chen, and A. Tin et al. CUBN is a gene locus for albuminuria J Am Soc Nephrol 22 2011 555 570
75. E.J. Lamb, F. MacKenzie, and P.E. Stevens How should proteinuria be detected and measured? Ann Clin Biochem 46 2009 205 217
76. W.G. Miller Urine albumin: recommendations for standardization Scand J Clin Lab Invest Suppl 241 2008 71 72
77. A.S. Levey, J.J. Gassman, and P.M. Hall et al. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group J Am Soc Nephrol 1 1991 1087 1094
78. S. Klahr, A.S. Levey, and G.J. Beck et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med 330 1994 877 884
79. J.T. Wright Jr., G. Bakris, and T. Greene et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2002 2421 2431
80. B.O. Eriksen, and O.C. Ingebretsen The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age Kidney Int 69 2006 375 382
81. C. Jones, P. Roderick, and S. Harris et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease Nephrol Dial Transplant 21 2006 2133 2143
82. A. Levin, O. Djurdjev, and M. Beaulieu et al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort Am J Kidney Dis 52 2008 661 671
83. C. Baigent, M.J. Landray, and C. Reith et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial Lancet 377 2011 2181 2192